In a large cohort study from the United States involving more than 18,000 overweight or obese individuals, Rodriguez et al reported that the average weight loss after one year was 8.3% with semaglutide and 15.3% with tirzepatide
For starters, your brain is about 60% fat, so you need to keep it supplied with good fats
Only one in 12 remain on a GLP-1 drug for obesity at three years owenhaskins Jun 26, 2025 2 min read Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)
GLP-1 drugs show how quickly innovation can outpace policy, how cost pressures are resolved through access restrictions, and how deeply entrenched inequities shape who benefits from medical progress
It's not a fringe concern, it's a documented trend tracked across the nutrition industry
Individual results can vary depending on factors like diet, exercise habits, and how your body responds to semaglutide GLP-1